Lorna Ewart

Lorna Ewart

Auto-generated profile, based on publicly available information

Lorna Ewart

Emulate Inc., Boston, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KJKyung-Jin Jang
Kyung-Jin Jang
MOMonicah A. Otieno
Monicah A. Otieno
JRJaney Ronxhi
Janey Ronxhi
HLHeng-Keang Lim
Heng-Keang Lim
LELorna Ewart
Lorna Ewart
GHGeraldine A. Hamilton
Geraldine A. Hamilton
A rat, dog, and human Liver-Chip designed using microengineered Organs-on-Chips technology recapitulates species-specific drug toxicities.

6 December 2022 in Communications Medicine
Verified
Journal Article
Open access
PDF file
LELorna Ewart
Lorna Ewart
AAAthanasia Apostolou
Athanasia Apostolou
SBSkyler A. Briggs
Skyler A. Briggs
CCChristopher V. Carman
Christopher V. Carman
JCJake T. Chaff
Jake T. Chaff
DLDaniel Levner
Daniel Levner
Background: Conventional preclinical models often miss drug toxicities, meaning the harm these drugs pose to humans is only realized in clinical trials or when they make it to market. This has caused the pharmaceutical industry to waste considerable time and resources developing drugs destined to fail. Organ-on-a-Chip technology has the potential to improve success in drug development pipelines, as it can recapitulate organ-level pathophysiology and clinical responses; however, systematic and quantitative evaluations of Organ-Chips’ predictive value have not yet been reported. Methods: 870 Liver-Chips were analyzed to determine their ability to predict drug-induced liver injury caused by small molecules identified as benchmarks by the Innovation and Quality consortium, who has published guidelines defining criteria for qualifying preclinical models. An economic analysis was also performed to measure the value Liver-Chips could offer if they were broadly adopted in supporting toxicity-related decisions as part of preclinical development workflows. Results: Here, we show that the Liver-Chip met the qualification guidelines across a blinded set of 27 known hepatotoxic and non-toxic drugs with a sensitivity of 87% and a specificity of 100%. We also show that this level of performance could generate over $3 billion annually for the pharmaceutical industry through increased small-molecule R&D productivity. Conclusions: The results of this study show how incorporating predictive Organ-Chips into drug development workflows could substantially improve drug discovery and development, allowing manufacturers to bring safer, more effective medicines to market in less time and at lower costs.

8 October 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
IPIosif Pediaditakis
Iosif Pediaditakis
KKKonstantia R. Kodella
Konstantia R. Kodella
DMDimitris V. Manatakis
Dimitris V. Manatakis
CLChristopher Y. Le
Christopher Y. Le
CHChris D. Hinojosa
Chris D. Hinojosa
KKKatia Karalis
Katia Karalis
Parkinson’s disease and related synucleinopathies are characterized by the abnormal accumulation of alpha-synuclein aggregates, loss of dopaminergic neurons, and gliosis of the substantia nigra. Although clinical evidence and in vitro studies indicate disruption of the Blood-Brain Barrier in Parkinson’s disease, the mechanisms mediating the endothelial dysfunction is not well understood. Here we leveraged the Organs-on-Chips technology to develop a human Brain-Chip representative of the substantia nigra area of the brain containing dopaminergic neurons, astrocytes, microglia, pericytes, and microvascular brain endothelial cells, cultured under fluid flow. Our αSyn fibril-induced model was capable of reproducing several key aspects of Parkinson’s disease, including accumulation of phosphorylated αSyn (pSer129-αSyn), mitochondrial impairment, neuroinflammation, and compromised barrier function. This model may enable research into the dynamics of cell-cell interactions in human synucleinopathies and serve as a testing platform for target identification and validation of novel therapeutics.

21 February 2020 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
MPMatthew F. Peters
Matthew F. Peters
ACAllison L. Choy
Allison L. Choy
CPCarmen Pin
Carmen Pin
DLDerek J. Leishman
Derek J. Leishman
AMAnnie Moisan
Annie Moisan
KKKyle L. Kolaja
Kyle L. Kolaja
Drug-induced gastrointestinal toxicities (DI-GITs) are among the most common adverse events in clinical trials.

15 February 2024 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
DRDarwin Reyes
Darwin Reyes
MEMandy B. Esch
Mandy B. Esch
LELorna Ewart
Lorna Ewart
Rohollah NasiriRohollah Nasiri
Rohollah Nasiri
AHAnna Herland
Anna Herland
Nureddin AshammakhiNureddin Ashammakhi
Nureddin Ashammakhi
Limitations with cell cultures and experimental animal-based studies have had the scientific and industrial communities searching for new approaches that can provide reliable human models for applications such as drug development, toxicological assessment, and in vitro pre-clinical evaluation. This has resulted in the development of microfluidic-based cultures that may better represent organs and organ systems in vivo than conventional monolayer cell cultures. Although there is considerable interest from industry and regulatory bodies in this technology, several challenges need to be addressed for it to reach its full potential. Among those is a lack of guidelines and standards. Therefore, a multidisciplinary team of stakeholders was formed, with members from the US Food and Drug Administration (FDA), the National Institute of Standards and Technology (NIST), European Union, academia, and industry, to provide a framework for future development of guidelines/standards governing engineering concepts of organ-on-a-chip models. The result of this work is presented here for interested parties, stakeholders, and other standards development organizations (SDOs) to foster further discussion and enhance the impact and benefits of these efforts.

15 September 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
TKTomasz Kostrzewski
Tomasz Kostrzewski
SSSophie Snow
Sophie Snow
ABAnya Lindström Battle
Anya Lindström Battle
SPSamantha Peel
Samantha Peel
ZAZahida Ahmad
Zahida Ahmad
DHDavid Hughes
David Hughes
Non-alcoholic steatohepatitis (NASH) is a common form of chronic liver disease characterised by lipid accumulation, infiltration of immune cells, hepatocellular ballooning, collagen deposition and liver fibrosis. There is a high unmet need to develop treatments for NASH. We have investigated how liver fibrosis and features of advanced clinical disease can be modelled using an in vitro microphysiological system (MPS). The NASH MPS model comprises a co-culture of primary human liver cells, which were cultured in a variety of conditions including+/− excess sugar, fat, exogenous TGFβ or LPS. The transcriptomic, inflammatory and fibrotic phenotype of the model was characterised and compared using a system biology approach to identify conditions that mimic more advanced clinical disease. The transcriptomic profile of the model was shown to closely correlate with the profile of patient samples and the model displayed a quantifiable fibrotic phenotype. The effects of Obeticholic acid and Elafibranor, were evaluated in the model, as wells as the effects of dietary intervention, with all able to significantly reduce inflammatory and fibrosis markers. Overall, we demonstrate how the MPS NASH model can be used to model different aspects of clinical NASH but importantly demonstrate its ability to model advanced disease with a quantifiable fibrosis phenotype.